GlassScriptPhysician profile
Omar T Khan
NPI 1144480310
$144,731.63
in general payments reported to CMS, 2019-2025
48 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,505 · 2021: $15K · 2022: $15K · 2023: $19K · 2024: $29K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $17K · Food and Beverage: $13K · Honoraria: $8,063 · Travel and Lodging: $3,980 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,925.00 |
| Consulting Fee | $17,382.00 |
| Food and Beverage | $12,964.74 |
| Honoraria | $8,062.50 |
| Travel and Lodging | $3,979.76 |
| Education | $119.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $40,328.70 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $38,104.48 | 2019-2023 | Krystexxa |
| Amgen INC. | $34,954.01 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| E.R. Squibb & Sons, L.L.C. | $10,785.94 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $4,443.90 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $3,623.58 | 2019-2025 | |
| Pfizer INC. | $3,016.92 | 2019-2025 | |
| Sobi, INC | $2,078.16 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,514.24 | 2019-2025 | |
| Gilead Sciences, INC. | $1,320.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.50 | 2019-2023 | Ofev |
| Lilly USA, LLC | $519.93 | 2019-2024 | Taltz |
| Radius Health, INC. | $476.57 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $380.23 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $366.09 | 2019-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.